DEWIZ
10.8.2021 11:51:08 CEST | Business Wire | Press release
deWiz’s Board of Directors, including co-founders Christian Bergh and Markus Westerberg, have announced Laszlo Varga as deWiz’s new Chief Executive Officer, starting August 16. Varga will apply his extensive experience leading e-commerce businesses like Gents and EuroFlorist to deWiz’s go-to-market strategy in golf and help develop strategic extensions for deWiz’s technology with other sports and disciplines. As CEO, Varga will oversee the start-up’s transition to a comprehensive global strategy by aligning all aspects of deWiz businesses using his expertise across consumer products, digital marketing, and direct sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005498/en/
Debuting this summer, deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback and high-precision swing data that accelerates golfers’ pace of learning and adds consistency. deWiz’s introduction to the golf and business world has already created a “buzz” with it being described by Forbes as looking to bring a “jolt to the golf training aid market ;” being profiled in Sweden’s leading financial media, Dagens Industri ; and being featured in Sport Techie’s Startups series .
“On behalf of my co-founder Markus and the deWiz board, I am thrilled to have Laszlo join our journey as we strive to help golfers improve faster with our science-backed technology as their competitive edge. As I continue as Chief Operations Officer for deWiz and as a board member, it’s a testament to how much we’ve accomplished since founding the company to have attracted somebody of Laszlo’s caliber and business acumen to lead our global strategy moving forward,” said Christian Bergh, co-founder and COO of deWiz.
“I’m super excited and proud to join the deWiz team. The product is truly revolutionary in helping athletes improve their performance by combining neural science with instant feedback and unmatched data capture. There is nothing else like deWiz in the golf market and the feedback we've gotten from the early users is overwhelmingly positive. With my experience and understanding of global e-commerce and direct sales to consumers, I hope to contribute to the accelerated growth and success of this awesome company that is on the front edge of innovation," said Laszlo Varga, CEO of deWiz.
Varga has a strong background in multi-national e-commerce and direct-to-consumer sales. Prior to joining deWiz, Laszlo was the CEO of Gents, a brand and online retailer for male grooming products. Before joining Gents, Varga was the CEO of Euroflorist, Europe’s largest flowers by wire company where he had a long and successful career, serving previously as Chief Operations Officer and Online Director, heading the online transition of sales. Varga’s entrepreneurial spirit and busines building skillset is also relied upon as a board member for Gents, CoolStuff and BoneProx. Varga is based in Malmö, Sweden, where he has spent the majority of his professional career after graduating from San Diego State University and competing at an elite level in kayaking.
DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz’s has been in development for more than five years and has attracted an impressive roster of ambassadors, including 2020 U.S. Open Champion Bryson DeChambeau, 10-time Major Champion Annika Sorenstam, 3-time Major Champion Vijay Singh, 2-time Major Champion Lydia Ko, 2016 Open Champion Henrik Stenson, 2019 Houston Open Champion Lanto Griffin and 2-time World Long Drive Champion Tim Burke. deWiz’s user-friendly app and wearable tech tracks the precise position of a golfer’s hands throughout their swing, providing a 3D analysis and delivering data showcasing Transition , Length of Backswing , Wedge Distance and Tempo . These unique deWiz data points provide measurable metrics that any avid golfer, teaching professional or world-class player can utilize to efficiently refine their swing. Currently for sale for 699 USD, deWiz is available across the United States, Canada, Europe, and South Korea (more markets opening regularly – visit the website for the latest updates). Please visit dewizgolf.com for more details on how to improve your swing faster or download the app to demo its features via Apple’s App Store or Google Play.
ABOUT deWiz
The deWiz golf training platform has been developed by former European Tour pro, PGA of Sweden certified instructor and motor learning author, Markus Westerberg, and entrepreneur and technology business leader Christian Bergh. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world elevate their enjoyment of the game through innovative technology that accelerates the pace of learning. deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback that is based on a scientific approach of breaking cycles within motor learning and propelling golfers to improve faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
